Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yan‐Miao Huo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4730-7184; OpenAlex author ID A5024260926, A5129606199. Sources: OpenAlex.

Their work

Papers
43 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
84
Papers, trials and grants by year

2014: 2 papers · 2015: 4 papers · 2016: 4 papers · 2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 4 papers · 2021: 5 papers · 2022: 5 papers · 2023: 3 papers · 2024: 5 papers · 2025: 1 paper · 2026: 3 papers

Papers 43

  1. A cholesterol-dependent LRRC8A-caveolin-1 axis sustains KRAS/EGFR signaling, ribosome biogenesis and growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-026-03864-z↗
  2. A Malignant Subpopulation of H2AFZ+ Cells Interacts with Myeloid Cells to Promote an Anti-inflammatory Microenvironment and Drive Hepatic Metastasis, Revealing… Co-author DOI 10.1158/1078-0432.ccr-25-3359↗
  3. OSBPL10 Drives Lipophagy-Mediated Lipid Mobilization to Promote Pancreatic Ductal Adenocarcinoma Progression. Last author DOI 10.7150/ijbs.125552↗
  4. TMEM105 modulates disulfidptosis and tumor growth in pancreatic cancer via the β-catenin-c-MYC-GLUT1 axis. Co-author DOI 10.7150/ijbs.104598↗
  5. AGFG1 increases cholesterol biosynthesis by disrupting intracellular cholesterol homeostasis to promote PDAC progression. Co-author DOI 10.1016/j.canlet.2024.217130↗
  6. A CLIC1 network coordinates matrix stiffness and the Warburg effect to promote tumor growth in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2024.114633↗
  7. Oncogenic GALNT5 confers FOLFIRINOX resistance via activating the MYH9/ NOTCH/ DDR axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-024-07110-w↗
  8. The lncRNA LINC01605 promotes the progression of pancreatic ductal adenocarcinoma by activating the mTOR signaling pathway. Last author DOI 10.1186/s12935-024-03440-z↗
  9. A Nutrient-Deficient Microenvironment Facilitates Ferroptosis Resistance via the FAM60A-PPAR Axis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.34133/research.0300↗
  10. Analysis of cuproptosis-related lncRNA signature for predicting prognosis and tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1007/s10495-023-01843-3↗
  11. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Last author DOI 10.1007/s13402-022-00741-1↗
  12. ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. Last author DOI 10.1016/j.hbpd.2022.04.005↗
  13. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… Co-author DOI 10.1002/ctm2.1126↗
  14. IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. Co-author DOI 10.1007/s13402-022-00670-z↗
  15. SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
  16. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
  17. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil. Co-author DOI 10.3389/fimmu.2022.983116↗
  18. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis. First author DOI 10.1002/1878-0261.12970↗
  19. CD74 promotes perineural invasion of cancer cells and mediates neuroplasticity via the AKT/EGR-1/GDNF axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.016↗
  20. Single-cell RNA sequencing reveals that targeting HSP90 suppresses PDAC progression by restraining mitochondrial bioenergetics. Co-author DOI 10.1038/s41389-021-00311-4↗
  21. ERO1L Promotes Hepatic Metastasis through Activating Epithelial-Mesenchymal Transition (EMT) in Pancreatic Cancer. Co-author DOI 10.1155/2021/5553425↗
  22. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic duc… Co-author DOI 10.1186/s13059-020-02222-w↗
  23. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-19-2689↗
  24. Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-20-0111↗
  25. Molecular markers associated with perineural invasion in pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2020.11866↗
  26. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer. Co-author DOI 10.7150/thno.45124↗
  27. Transcription factor NFAT5 contributes to the glycolytic phenotype rewiring and pancreatic cancer progression via transcription of PGK1. Co-author DOI 10.1038/s41419-019-2072-5↗
  28. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/8656282↗
  29. SFRP4 is a prognostic marker and correlated with Treg cell infiltration in pancreatic ductal adenocarcinoma. Co-author PMID 30906634↗
  30. IL22RA1/STAT3 Signaling Promotes Stemness and Tumorigenicity in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-17-3131↗
  31. Decreased expression of USP9X is associated with poor prognosis in Chinese pancreatic ductal adenocarcinoma patients. First author DOI 10.3892/ol.2018.8452↗
  32. The role of Dickkopf-1 as a potential prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384101.2017.1356510↗
  33. High Expression of FAM83B Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma and Correlates with Cell Cycle and Cell Proliferation. Co-author DOI 10.7150/jca.20086↗
  34. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep33535↗
  35. Efficacy of Neo-Adjuvant Chemoradiotherapy for Resectable Pancreatic Adenocarcinoma: A PRISMA-Compliant Meta-Analysis and Systematic Review. Co-author DOI 10.1097/md.0000000000003009↗
  36. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.6772↗
  37. Elevated expression of CTHRC1 predicts unfavorable prognosis in patients with pancreatic ductal adenocarcinoma. Co-author PMID 27648368↗
  38. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep10575↗
  39. Corrigendum: Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/srep15869↗
  40. High expression of DDR1 is associated with the poor prognosis in Chinese patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-015-0202-1↗
  41. High expression of WISP-1 correlates with poor prognosis in pancreatic ductal adenocarcinoma. Co-author PMID 26550461↗
  42. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC. Co-author DOI 10.1016/j.pan.2014.07.013↗
  43. Effect of CD74 on the prognosis of patients with resectable pancreatic cancer. Co-author DOI 10.1016/s1499-3872(14)60011-4↗

Closest collaborators

The 25 strongest of 84 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongwei Sun · 35 shared papers, 2014–2026 · strength 3.75
  2. Minwei Yang · 29 shared papers, 2015–2026 · strength 3.30
  3. Jian‐Yu Yang · 26 shared papers, 2015–2026 · strength 2.57
  4. Rong Hua · 27 shared papers, 2014–2024 · strength 2.39
  5. Dejun Liu · 21 shared papers, 2014–2024 · strength 2.04
  6. Xueliang Fu · 21 shared papers, 2015–2024 · strength 1.94
  7. Hong‐Fei Yao · 10 shared papers, 2022–2025 · strength 1.69
  8. Jia-Hao Zheng · 10 shared papers, 2022–2024 · strength 1.64
  9. Zong‐Hao Duan · 8 shared papers, 2023–2026 · strength 1.61
  10. Shu‐Heng Jiang · 13 shared papers, 2015–2026 · strength 1.56
  11. Junfeng Zhang · 13 shared papers, 2016–2026 · strength 1.42
  12. Qin-Yuan Jia · 7 shared papers, 2023–2025 · strength 1.26
  13. Li-Peng Hu · 7 shared papers, 2020–2026 · strength 1.05
  14. Ruizhe He · 8 shared papers, 2019–2023 · strength 0.95
  15. Yu-Heng Zhu · 5 shared papers, 2023–2025 · strength 0.91
  16. Zhigang Zhang · 10 shared papers, 2015–2026 · strength 0.89
  17. Junfeng Zhang · 9 shared papers, 2014–2024 · strength 0.77
  18. Wei Liu · 4 shared papers, 2020–2026 · strength 0.70
  19. Wei Chiang Liu · 7 shared papers, 2016–2022 · strength 0.66
  20. Dejun Liu · 6 shared papers, 2016–2024 · strength 0.60
  21. Jian Yang · 4 shared papers, 2022–2024 · strength 0.58
  22. Yifan Yin · 3 shared papers, 2024 · strength 0.53
  23. Linli Yao · 3 shared papers, 2021–2026 · strength 0.51
  24. Wei Liu · 5 shared papers, 2014–2024 · strength 0.45
  25. Dapeng Xu · 3 shared papers, 2022–2023 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.